These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 25831238)

  • 41. Impact of acquired del(17p) in multiple myeloma.
    Lakshman A; Painuly U; Rajkumar SV; Ketterling RP; Kapoor P; Greipp PT; Dispenzieri A; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
    Blood Adv; 2019 Jul; 3(13):1930-1938. PubMed ID: 31248884
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients.
    Jian Y; Chen X; Zhou H; Zhu W; Liu N; Geng C; Chen W
    Medicine (Baltimore); 2016 May; 95(19):e3521. PubMed ID: 27175647
    [TBL] [Abstract][Full Text] [Related]  

  • 43. p53 nuclear expression correlates with hemizygous TP53 deletion and predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with lenalidomide.
    Chen MH; Qi CX; Saha MN; Chang H
    Am J Clin Pathol; 2012 Feb; 137(2):208-12. PubMed ID: 22261445
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS.
    Romaniuk W; Bolkun L; Kalita J; Galar M; Bernatowicz M; Ostrowska H; Kloczko J
    Ann Hematol; 2018 Oct; 97(10):1879-1887. PubMed ID: 29946907
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction.
    Skerget M; Skopec B; Zadnik V; Zontar D; Podgornik H; Rebersek K; Furlan T; Cernelc P
    Acta Haematol; 2018; 139(4):228-234. PubMed ID: 29920491
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chromosome 13q deletion and IgH abnormalities may be both masked by near-tetraploidy in a high proportion of multiple myeloma patients: a combined morphology and I-FISH analysis.
    Koren-Michowitz M; Hardan I; Berghoff J; Yshoev G; Amariglio N; Rechavi G; Nagler A; Trakhtenbrot L
    Cancer Lett; 2007 Oct; 255(2):307-14. PubMed ID: 17590504
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.
    Neben K; Lokhorst HM; Jauch A; Bertsch U; Hielscher T; van der Holt B; Salwender H; Blau IW; Weisel K; Pfreundschuh M; Scheid C; Dührsen U; Lindemann W; Schmidt-Wolf IG; Peter N; Teschendorf C; Martin H; Haenel M; Derigs HG; Raab MS; Ho AD; van de Velde H; Hose D; Sonneveld P; Goldschmidt H
    Blood; 2012 Jan; 119(4):940-8. PubMed ID: 22160383
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens.
    Bochtler T; Hegenbart U; Kunz C; Granzow M; Benner A; Seckinger A; Kimmich C; Goldschmidt H; Ho AD; Hose D; Jauch A; Schönland SO
    J Clin Oncol; 2015 Apr; 33(12):1371-8. PubMed ID: 25779559
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?
    Leiba M; Duek A; Amariglio N; Avigdor A; Benyamini N; Hardan I; Zilbershats I; Ganzel C; Shevetz O; Novikov I; Cohen Y; Ishoev G; Rozic G; Nagler A; Trakhtenbrot L
    Genes Chromosomes Cancer; 2016 Sep; 55(9):710-8. PubMed ID: 27152944
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Distinct predictive impact of FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients.
    Byun JM; Shin DY; Hong J; Kim I; Kim HK; Lee DS; Koh Y; Yoon SS
    Cancer Med; 2018 Mar; 7(3):831-841. PubMed ID: 29380550
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
    Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Frequency of del(12p) is commonly underestimated in myelodysplastic syndromes: Results from a German diagnostic study in comparison with an international control group.
    Braulke F; Müller-Thomas C; Götze K; Platzbecker U; Germing U; Hofmann WK; Giagounidis AA; Lübbert M; Greenberg PL; Bennett JM; Solé F; Slovak ML; Ohyashiki K; Le Beau MM; Tüchler H; Pfeilstöcker M; Hildebrandt B; Aul C; Stauder R; Valent P; Fonatsch C; Bacher U; Trümper L; Haase D; Schanz J
    Genes Chromosomes Cancer; 2015 Dec; 54(12):809-17. PubMed ID: 26355708
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21.
    Nahi H; Våtsveen TK; Lund J; Heeg BM; Preiss B; Alici E; Møller MB; Wader KF; Møller HE; Grøseth LA; Østergaard B; Dai HY; Holmberg E; Gahrton G; Waage A; Abildgaard N
    Eur J Haematol; 2016 Jan; 96(1):46-54. PubMed ID: 25779478
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genomic aberrations and survival of patients with light-chain-only multiple myeloma undergoing autologous stem cell transplantation.
    Jiang N; Qi C; Trieu Y; Reece D; Chang H
    Biol Blood Marrow Transplant; 2011 Dec; 17(12):1790-5. PubMed ID: 21658460
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prognostic significance of copy-number alterations in multiple myeloma.
    Avet-Loiseau H; Li C; Magrangeas F; Gouraud W; Charbonnel C; Harousseau JL; Attal M; Marit G; Mathiot C; Facon T; Moreau P; Anderson KC; Campion L; Munshi NC; Minvielle S
    J Clin Oncol; 2009 Sep; 27(27):4585-90. PubMed ID: 19687334
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no additional prognostic value.
    An G; Xu Y; Shi L; Shizhen Z; Deng S; Xie Z; Sui W; Zhan F; Qiu L
    Haematologica; 2014 Feb; 99(2):353-9. PubMed ID: 24213147
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.
    Kadam Amare PS; Jain H; Nikalje S; Sengar M; Menon H; Inamdar N; Subramanian PG; Gujral S; Shet T; Epari S; Nair R
    Indian J Med Res; 2016 Oct; 144(4):536-543. PubMed ID: 28256461
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China.
    Lai YY; Huang XJ; Cai Z; Cao XS; Chen FP; Chen XQ; Chen BA; Fang MY; Feng JF; Fu WL; Guo HY; Hou M; Hou J; Hu Y; Hu XT; Hu XM; Huang LQ; Jin J; Li JY; Li J; Li W; Liang YM; Liu T; Liu QF; Liu YH; Mao P; Ouyang J; Qiu LG; Qiu L; Shao CK; Shi B; Song YP; Sun ZM; Wang QS; Wang C; Wang JM; Wang YS; Wang Z; Wu JB; Wu YX; Xia RX; Xue YQ; Yang BZ; Yang G; Yang ZL; Yu L; Yuan Z; Zhang S; Zhang Y; Zhao HG; Zhao L; Zhou DB; Zou SH; Zhu YF
    Chin Med J (Engl); 2012 Aug; 125(15):2663-70. PubMed ID: 22931972
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [IgA multiple myeloma with adverse prognostic factors--a case report].
    Kumiega B; Wolska-Smoleń T; Skotnicki AB
    Przegl Lek; 2009; 66(8):459-63. PubMed ID: 20043594
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma.
    Chang H; Ning Y; Qi X; Yeung J; Xu W
    Br J Haematol; 2007 Oct; 139(1):51-4. PubMed ID: 17854306
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.